The narrative that peptides are somehow experimental or fringe is fifteen years out of date. Several peptides have already completed full FDA approval. Over forty more are in active Phase II or Phase III clinical trials. Pharmaceutical companies have poured billions into commercialising compounds that high-end longevity clinics have been using off-label since the early 2010s.
This article maps where each major research peptide actually sits in the regulatory pipeline, approved, in trials, or still in the research-only category, so you can see the trajectory with your own eyes. The data is public. The approvals are on record. The trials are searchable on ClinicalTrials.gov. This is not speculation. It is the regulatory reality.
Why this matters. FDA approval is the highest standard of clinical evidence in the world. When a compound makes it through Phase III trials and gets approved, the safety and efficacy data is unambiguous. Knowing which peptides have cleared that bar, and which are in active trials, tells you how mature the science actually is.
These compounds have completed full Phase III trials and received FDA marketing approval for specific indications:
| Peptide | Status | Approved Indication |
|---|---|---|
| GLP-1 RC-S | Approved | Type-2 diabetes, chronic weight management |
| GLP-1 RC-T (the licensed pharmaceutical/the licensed pharmaceutical) | Approved | Type-2 diabetes, chronic weight management |
| Tesamorelin (Egrifta) | Approved | HIV-associated visceral lipodystrophy |
| Sermorelin | Approved | Pediatric growth hormone deficiency |
| Liraglutide (Saxenda/Victoza) | Approved | Type-2 diabetes, chronic weight management |
| Dulaglutide (Trulicity) | Approved | Type-2 diabetes |
| Exenatide (Byetta/Bydureon) | Approved | Type-2 diabetes |
Each of these has a documented mechanism, a peer-reviewed dataset running to tens of thousands of participants, and a well-characterised safety profile. GLP-1 RC-S alone has been studied in over 60,000 patients across the STEP, SUSTAIN and SELECT trial programs.
The next wave of peptide therapeutics is in various phases of FDA clinical investigation. Some of the notable programs:
| Peptide | Status | Investigated For |
|---|---|---|
| GLP-1 RC-R | Phase III | Obesity (triple agonist, GLP-1/GIP/glucagon) |
| Cagrilintide + GLP-1 RC-S | Phase III | Obesity (amylin + GLP-1 co-agonism) |
| Survodutide | Phase III | Obesity, NASH |
| Orforglipron | Phase III | Oral GLP-1 agonist (diabetes, obesity) |
| BPC-157 analogs | Phase II | GI inflammation, tissue repair |
| Thymosin Alpha-1 | Phase II/III | Chronic hepatitis, immune modulation (approved ex-US) |
| DSIP / sleep peptides | Phase II | Sleep architecture, stress recovery |
These compounds have strong peer-reviewed research behind them but have not yet entered the FDA approval pipeline (either because of patent economics, because they’re endogenous compounds, or because investigation has stayed primarily in academic and international settings). For context on the agency’s 2023 ruling that kept several of these peptides off the compounding-pharmacy “bulks list” for human use - and why that ruling actually reinforces, rather than contradicts, the research-use-only category - see our dedicated explainer on the 2023 FDA peptide compounding decision.
| Peptide | Status | Research Area |
|---|---|---|
| BPC-157 | Research | Tissue repair, GI protection (30+ published studies) |
| GHK-Cu | Research | Gene expression, skin remodelling (4,382 genes modulated) |
| TB-500 / Thymosin Beta-4 | Research | Angiogenesis, systemic tissue repair |
| CJC-1295 / Ipamorelin | Research | Pulsatile GH release, sleep, lean mass |
| Epitalon | Research | Telomerase, cellular ageing markers |
| Semax / Selank | Research | Cognitive, anxiolytic (approved in Russia) |
| MOTS-c | Research | Mitochondrial function, metabolic health |
The GLP-1 gold rush, GLP-1 RC-S and GLP-1 RC-T generating tens of billions in annual revenue, has fundamentally changed how pharma views peptide therapeutics. What was once a niche category is now the most important growth vector in the industry. Roche, Pfizer and Amgen are all aggressively expanding their peptide pipelines.
The irony is that many of these “new” compounds are variations on peptides the longevity clinics have been running for a decade. GLP-1 RC-R is a triple GLP-1/GIP/glucagon agonist. Cagrilintide builds on amylin biology first described in the 1980s. The basic class of compounds is well-trodden. What pharma brings is Phase III validation, regulatory clearance and insurance reimbursement, not fundamental discovery.
The bottom line. Peptide therapy is not “experimental.” It is a validated category with approved drugs, active trials, billion-dollar revenue streams, and a deep research literature. The compounds the elite have been running privately for fifteen years are the same ones pharma is now commercialising, just with a patent wrapper and a sales force. That’s the regulatory reality.
Every compound in our catalog is independently verified by Janoshik and Freedom Diagnostics at >99% purity. Research-grade, sealed, shipped direct.
Browse the catalog